|
Other Equity and Common Stock Transactions (Details 2) (USD $)
|
0 Months Ended | 12 Months Ended | |
|---|---|---|---|
|
Dec. 18, 2012
|
Jul. 31, 2014
|
Jul. 31, 2013
|
|
| Other Equity and Common Stock Transactions | |||
| Authorized issuance of shares to University of South Florida Research Foundation | 150,000 | ||
| Value of shares issued to the University of South Florida Research Foundation | $ 34,500 | $ 34,500 | |
| First payment upon the start of future phase II clinical trial | 50,000 | ||
| Payment upon the start of future phase III clinical trial | 100,000 | ||
| Payment upon FDA approval | 250,000 | ||
| Dividends paid | $ 0 | $ 0 | |
| X | ||||||||||
|
- Definition
Represents the payment due on FDA approval under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the payment due on start of future phase II clinical trial under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the payment due on start of future phase III clinical trial under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of shares issued for noncash consideration for development stage entities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of shares issued for noncash consideration for development stage entities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|